Last reviewed · How we verify
NCT07157228
Clinical Characteristics, Etiologies, and Outcomes of Patients With Haematochezia at Al-Rajhi University Hospital.
trial in Haematochezia in 70 participants. Not yet recruiting.
1 October 2026
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 1 October 2025 |
| Primary completion | 1 October 2026 |
| Estimated completion | 31 October 2026 |
Conditions studied
- Haematochezia — all drugs for Haematochezia →
Sponsor
Assiut University
Who can join
18 and older, any sex, with Haematochezia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Haematochezia is the passage of bright red or maroon blood or blood clots from the rectum, usually originates from a source in lower parts of the gastrointestinal (GI) tract * In addition, haematochezia can be seen in patients with brisk upper gastrointestinal bleeding (UGIB). The underlying etiology can vary from life threatening variceal bleeding to clinically insignificant haemorrhoidal bleeding . The most common etiology is diverticular bleeding, which accounts for 20% to 55% of cases, followed by intestinal ischemia, inflammatory bowel diseases, anorectal disorders, and neoplasia, which each accounting for around 10% of cases * LGIB can be mild and intermittent or moderate or severe . Patients with mild bleeding can be electively evaluated as outpatients. While, those with severe bleeding should be hospitalized for management Acute or severe LGIB has an incidence of 20-30 cases/100,000 person years and accounts for 20% of GI bleeds (7-8). The overall mortality rate of LGIB is 2-4% . Clinical data available at the time of initial patient evaluation can be used to identify patients at high risk for severe bleeding and other adverse outcomes. Several scoring systems have been developed to assess risk in acute LGIB . To the best of our knowledge, no Egyptian study has addressed the outcome of patients with haematochezia presented at the endoscopy units or has evaluated the clinical utility of risk scores in assessment of patients admitted to hospitals with acute haematochezia. Therefore, we need to study the short-term outcomes of patients with haematochezia (and their predictors) after being managed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07157228
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07157228 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 5 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07157228.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing